Premium
Belimumab treatment in rhupus: A case report with severe skin involvement
Author(s) -
Castillo Dayer Paloma Valentina,
Lozano Rivas Nuria,
Martínez Ferrín Javier José,
Victoria Martínez Ana Mercedes,
SánchezPedreño Guillen Paloma,
Marras FernándezCid Carlos
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13056
Subject(s) - medicine , belimumab , serositis , dermatology , rituximab , malar rash , rash , polyarthritis , abatacept , arthritis , immunology , autoantibody , antibody , b cell , b cell activating factor , anti nuclear antibody
Patients with rhupus characteristically exhibit symmetric polyarthritis and clinical manifestations suggestive of systemic lupus erythematosus (malar rash, photosensitivity, hematological manifestations, serositis, and/or skin involvement) and positive anti‐dsDNA. Treatment is unclear and it can include disease‐modifying rheumatic drugs like hydroxyl chloroquine, or methotrexate or, in refractory cases, rituximab or abatacept. We report a case of 31‐year‐old female who present with rhupus with skin acute lesions treated with belimumab. This is the first case of rhupus treated with this drug described in the literature.